Zur Hauptnavigation wechseln Zur Suche wechseln Zum Hauptinhalt wechseln

Carfilzomib-Revlimid-Dexamethasone Vs. Carfilzomib-Thalidomide-Dexamethasone Weekly (After 2 Twice Weekly Cycles) Followed By Carfilzomib Maintenance Vs. Control in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) - Interim Efficacy Analysis of Combined Data (AGMT MM-02): American Society of Hematology, 61th Annual Meeting, scientific session

  • Heinz Ludwig
  • , Siegfried Sormann
  • , Niklas Zojer
  • , Johannes Andel
  • , Bernd L. Hartmann
  • , Christoph Tinchon
  • , Eberhard Gunsilius
  • , Klaus Podar
  • , Alexander Egle
  • , Wolfgang Willenbacher
  • , Ewald Wöll
  • , Reinhard Ruckser
  • , Boris Bozic
  • , Maria-Theresa Krauth
  • , Andreas Petzer
  • , Clemens A. Schmitt
  • , Sigrid Machherndl-Spandl
  • , Hermine Agis
  • , Bruno Paiva
  • , Richard Greil

Publikation: Beitrag in Fachzeitschrift (peer-reviewed) › Konferenzbeitrag in Fachzeitschrift

Fingerprint

Untersuchen Sie die Forschungsthemen von „Carfilzomib-Revlimid-Dexamethasone Vs. Carfilzomib-Thalidomide-Dexamethasone Weekly (After 2 Twice Weekly Cycles) Followed By Carfilzomib Maintenance Vs. Control in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) - Interim Efficacy Analysis of Combined Data (AGMT MM-02): American Society of Hematology, 61th Annual Meeting, scientific session“. Zusammen bilden sie einen einzigartigen Fingerprint.
sortieren

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology

Nursing and Health Professions